11 completed, 11 recruiting, 5 terminated, 4 active not recruiting. 17 Phase 2, 16 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Small Lymphocytic Lymphoma (SLL): new trials by email Literature Review of Small Lymphocytic Lymphoma (SLL) trials Research Report on Small Lymphocytic Lymphoma (SLL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-08-06 |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-03-11 | 2026-10-22 |
| Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | European Research Initiative on CLL | 323 | 2025-12-18 | 2026-08-19 | |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 100 | 2025-10-15 | 2026-09-17 |
| Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor - Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL) | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 100 | 2025-07-17 | 2026-04-01 | |
| Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL Zanubrutinib, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Massachusetts General Hospital | 80 | 2025-05-16 | 2026-08-11 |
| A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting Lisocabtagene maraleucel - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 300 | 2025-02-04 | 2025-02-24 | |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | Recruiting | Vitebsk Regional Clinical Cancer Centre | 24 | 2024-05-14 | 2026-08-13 |
| A Case Crossover Study of Intermittent Fasting in CLL/SLL 5:2 Method (intermittent fasting regimen), 16/8 Method (intermittent fast regimen) - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Not applicable | Completed | British Columbia Cancer Agency | 6 | 2023-06-12 | 2024-03-08 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 572 | 2022-04-13 | 2026-07-02 |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma XL114 - Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) | Phase 1 | Terminated | Exelixis | 2 | 2022-04-12 | 2023-07-11 |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) Venetoclax, Zanubrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2022-02-18 | 2025-12-05 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | AbbVie | 20 | 2021-11-08 | 2026-10-21 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NX-2127 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 248 | 2021-05-05 | 2026-03-20 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies L-Bcl-2 antisense oligonucleotide - Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Active not recruiting | Bio-Path Holdings, Inc. | 30 | 2020-11-05 | 2025-02-24 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 81 | 2020-05-13 | 2026-07-10 |
| Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Acalabrutinib, Rituximab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | University of Rochester | 39 | 2019-03-25 | 2024-09-26 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (33) · Lymphoma, B-Cell, Marginal Zone (10) · Lymphoma, Mantle-Cell (10) · Lymphoma, Follicular (9) · Lymphoma, Large B-Cell, Diffuse (7) · Waldenstrom Macroglobulinemia (7) · Lymphoma (4) · Lymphoma, B-Cell (4) · Neoplasms (4) · Burkitt Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Chromosome 17 deletion (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2)
Chronic Disease (33) · Disease Attributes (33) · Hematologic Diseases (33) · Hemic and Lymphatic Diseases (33) · Immune System Diseases (33) · Immunoproliferative Disorders (33) · Leukemia, Lymphoid (33) · Neoplasms by Histologic Type (33) · Pathologic Processes (33) · Pathological Conditions, Signs and Symptoms (33) · Leukemia (32) · Leukemia, B-Cell (32) · Lymphatic Diseases (32) · Lymphoproliferative Disorders (31) · Neoplasms (29)
venetoclax (8) · Rituximab (4) · obinutuzumab (4) · acalabrutinib (3) · zanubrutinib (3) · Bendamustine Hydrochloride (2) · Lenalidomide (1) · ME-401 (1) · Methods (1) · ibrutinib (1) · idelalisib (1) · pembrolizumab (1) · pirtobrutinib (1) · plerixafor (1) · ublituximab (1)
AbbVie (4) · Nurix Therapeutics, Inc. (3) · Calibr, a division of Scripps Research (2) · MEI Pharma, Inc. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Acerta Pharma BV (1) · AstraZeneca (1) · Bio-Path Holdings, Inc. (1) · British Columbia Cancer Agency (1) · Dana-Farber Cancer Institute (1) · European Research Initiative on CLL (1) · Exelixis (1) · Genmab (1) · Genzyme, a Sanofi Company (1) · Gilead Sciences (1)
United States (24) · Italy (5) · Poland (4) · China (3) · France (3) · Spain (3) · United Kingdom (3) · Australia (2) · Canada (2) · Japan (2) · Netherlands (2) · Switzerland (2) · Austria (1) · Belarus (1) · Brazil (1)
Christopher MT Pleyer, M.D. (1) · Inhye E Ahn, MD (1) · Jacob Soumerai, MD (1) · Jianyong Li, MD (1) · Jie Jin, MD (1) · Julie Chang, MD (1) · Laura S Samples, M.D. (1) · Meghan Thompson, MD (1)
PMID 36375120, PMID 26472751, PMID 31352850, PMID 33259596, PMID 34398557, PMID 34508654, PMID 34515338, PMID 35157769, PMID 35835137, PMID 36548927, PMID 36689726, PMID 38151388, PMID 38889737, PMID 39322711, PMID 39705540, PMID 40472301, PMID 40809193, PMID 41843779, PMID 42411504, PMID 42431612, PMID 42541678
2023 (2), 2017 (1)